Keymed Biosciences Inc. (2162.HK)
Develops biological drugs to treat autoimmune diseases and cancer.
75.25-0.04%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+22.3%
The outlook
Keymed Biosciences trades at 75.25, comfortably above both its 50- and 200-day moving averages and positioned about two-thirds of the way up its 52-week range. Analyst consensus is strongly bullish with an average target around 28% above the current price. The data shows positive momentum and broad analyst support, though the stock is already well-elevated in its recent trading band.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range68% of the way from its 52-week low to high
Price targetAvg target +28% vs current price
Analyst price target
~12-month · 8 analysts96.05average target+27.6% vs now
Now 75.25
Low 84.95High 105.54
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$22.17B
52-wk high
89.75
52-wk low
44.66
50-day avg
69.12
200-day avg
62.61
Trailing P/E
—